Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin- Cytosine Deaminase-Uracil PhosphoribosylTransferase by Chen, Chun-Te
Texas Medical Center Library
DigitalCommons@The Texas Medical Center
UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences
12-2011
Dual Targeting of Tumor Angiogenesis and
Chemotherapy by Endostatin- Cytosine
Deaminase-Uracil PhosphoribosylTransferase
Chun-Te Chen
Follow this and additional works at: http://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Therapeutics Commons
This Dissertation (PhD) is brought to you for free and open access by the
Graduate School of Biomedical Sciences at DigitalCommons@The Texas
Medical Center. It has been accepted for inclusion in UT GSBS
Dissertations and Theses (Open Access) by an authorized administrator of
DigitalCommons@The Texas Medical Center. For more information,
please contact laurel.sanders@library.tmc.edu.
Recommended Citation
Chen, Chun-Te, "Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin- Cytosine Deaminase-Uracil
PhosphoribosylTransferase" (2011). UT GSBS Dissertations and Theses (Open Access). Paper 195.
 i
Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin-
Cytosine Deaminase-Uracil Phosphoribosyl Transferase 
 
By 
CHUN-TE CHEN 
APPROVED: 
____________________________ 
Mien-Chie Hung, Ph.D., Supervisor 
_____________________________ 
Dihua Yu, M.D., Ph.D. 
______________________________ 
Elsa R. Flores, Ph.D. 
______________________________ 
Gabriel Lopez-Berestein, M.D.  
______________________________ 
Zhen Fan, M.D. 
 
APPROVED: 
___________________________________ 
DEAN, THE UNIVERSITY OF TEXAS 
HEALTH SCIENCE CENTER AT HOUSTON 
GRADUATE SCHOOL OF BIOMEDICAL SCIENCES 
 ii
Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin-
Cytosine Deaminase-Uracil Phosphoribosyl Transferase 
 
A 
DISSERTATION 
 
Presented to the Faculty of 
The University of Texas 
Health Science Center at Houston 
and 
The University of Texas 
M. D. Anderson Cancer Center 
Graduate School of Biomedical Sciences 
In Partial Fulfillment 
Of the Requirements 
For the Degree of 
 
DOCTOR OF PHILOSOPHY 
 
by 
CHUN-TE CHEN, M.S. 
 
Houston, Texas 
December, 2011 
 iii
ACKNOWLEDGEMENTS  
 
I would like to express my utmost appreciation to all those who have assisted me 
throughout my graduation studies. First, I would like to thank to my mentor, Dr. Mien-
Chie Hung for accepting me to join his outstanding lab, for all his fully support and 
guidance, and taught me not only in scientific research but also the positive thinking 
when I face anything. It goes without saying that these are going to benefit to my 
future career. Second, I would like to thank all of my committee members for their 
valuable advice and guidance, Dr. Dihua Yu, Dr. Elsa Flores, Dr. Gabriel Lopez-
Berestein, Dr. Michael Van Dyke, Dr. Suyun Huang, Dr. Xiaomin Chen, and Dr. 
Zhen Fan. Third, I would like to thank my friends and colleagues who have helped 
me throughout my graduate study, especially to Dr. Hirohito Yamaguchi, Hong-Jen 
Lee, Yi Du, Heng-Huan Lee, Dr. Weiya Xia, Wen-Hsuan Yu, Dr. Chia-Jui Yen, Dr. 
Hui-Lung Sun, and Dr. Yan Wang. Last but not least, I would like give my 
appreciation to my wife EJ Chen (Yi-Chun Chen), my parents (Tsai-Yuan Chen and 
Chiung-Hua Chen Tsai), and my all family for their encouragement and support. 
 
 
 
 
 
 
 
 iv
Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin-
Cytosine Deaminase-Uracil Phosphoribosyl Transferase 
 
 
Publication No. _____________ 
 
 
 
Chun-Te Chen 
 
Supervisory Professor: Mien-Chie Hung, Ph.D. 
 
 
 
Abstract 
Antiangiogenesis is a promising anti-tumor strategy through inhibition tumor vascular 
formation to suppress tumor growth. Targeting specific VEGF/R has been shown 
therapeutic benefits in many cancer types and become a first approved 
antiangiogenic modalities by Food and Drug Administration (FDA) in United States. 
However, interruption of homeostasis in normal tissues that is likely due to the 
inhibition of VEGF/R signaling pathway induces unfavorable side effects. Moreover, 
cytostatic nature of antiangiogenic drugs frequently causes less tumor cell specific 
killing activity, and cancer cells escaped from cell death induced by these drugs 
even gain more malignant phenotypes, resulting in tumor invasion and metastasis. 
To overcome these issues, we developed a novel anti-tumor therapeutic EndoCD 
fusion protein which linked endostatin (Endo) to cytosine deaminase-uracil 
 v
phosphoribosyl transferase (CD). Endo targets unique tumor endothelial cells to 
provide tumor-specific antiangiogenesis activity and also carries CD to the local 
tumor area, where it serves nontoxic prodrug 5-fluorocytosine (5-FC) enzymatic 
conversion reaction to anti-metabolite chemotherapy drug 5-fluorouracil (5-FU). We 
demonstrated that 5-FU concentration was highly increased in tumor sites, resulting 
in high level of endothelial cells and tumor cells cytotoxic efficacy. Furthermore, 
EndoCD/5-FC therapy decreased tumor growth and colorectal liver metastasis 
incident compared with bevacizumab/5-FU treatment in human breast and colorectal 
liver metastasis orthotropic animal models. In cardiotoxicity safety profile, 
EndoCD/5-FC is a contrast to bevacizumab/5-FU; lower risk of cardiotoxicity 
induction or heart function failure was found in EndoCD/5-FC treatment than 
bevacizumab/5-FU does in mice. EndoCD/5-FC showed more potent therapeutic 
efficacy with high safety profile and provided stronger tumor invasion or metastasis 
inhibition than antiangiogenic drugs. Together, EndoCD fusion protein with 5-FC 
showed dual tumor targeting activities including antiangiogenesis and tumor local 
chemotherapy, and it could serve as an alternative option for antiangiogenic therapy. 
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CHAPTER 1: INTRODUCTION  
 
1.1 Tumor angiogenesis  
Tumors initially grow as avascular nodules by absorbing nutrient and removing 
waste through simple diffusion.  However, the growing beyond the size of 
approximately 1 mm diameter, the tumors require a delicate network of blood 
vessels to supply the nutrient and oxygen and remove waste products (Folkman, 
1971). The neovasculation process in tumors is so called “tumor angiogenesis” or “ 
angiogenesis switch” (Bergers and Benjamin, 2003). Classically, the transition of 
vascularization results from the angiogenesis switch driven by hypoxia. Tumors can 
produce several angiogenic activators to attract and activate endothelial cells, which 
is a critical step to mediate angiogenesis. Activation of endothelial cells initiates the 
cell proliferation, which in turn induces sprouting from exiting vessels, migration, and 
adhesion of endothelial cells to from a lumen. New formation of vessels under 
angiogenesis process continues to provide the necessary nutrients for cancer cells 
to grow and survive (Bergers and Benjamin, 2003). Moreover, recent literatures 
show that glioblastma cancer stem cell by itself can differentiate to endothelium 
phenotype, and the neo-formed vessels contribute to tumor progression and 
metastasis (Bautch, 2010; Ricci-Vitiani et al., 2010; Wang et al., 2010b). Tumor 
angiogenesis may therefore occur through two distinct mechanisms, which by 
attracting endothelial cells to from vessels (classical angiogenesis process), or by 
differentiating from cancer stem cells themselves.  
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1.2 Antiangiogenesis therapeutic strategy 
Classical angiogenesis process involves the interaction between angiogenesis 
factors as an inducer and endothelial cells as a responder. This angiogenesis 
process could be indirectly inhibited by neutralizing ligands (for example, vascular 
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)); blocking 
receptors tyrosine kinase activity (for example, vascular endothelial growth factor 
receptors (VEGFR), platelet-derived growth factor receptors (PDGFR)); or directly 
suppressed endothelial cell proliferation and migration. Therefore, these can be 
classified two kinds of method to inhibit angiogenesis process. One is “direct 
antiangiogenesis” and another one is “indirect antiangiogenesis” (Kerbel and 
Folkman, 2002). The inhibitors that serve direct antiangiogenesis include endostatin 
(O'Reilly et al., 1997), angiostatin (O'Reilly et al., 1994), tumstatin (Sudhakar et al., 
2003), and others (Cao, 2001). Most of them are endogenous proteins to be directly 
targeted to endothelial cells and restrain endothelial cell proliferation and migration. 
Indirect antiangiogenic inhibitors include VEGF (Kim et al., 1993) or PDGF 
monoclonal antibodies; or receptor tyrosine kinase inhibitor (TKI) (Ivy et al., 2009), 
which inhibit neovascularization by either neutralizing angiogenesis-inducing ligands 
or preventing receptors involved in angiogenesis pathways. Inhibition of tumor 
growth through antiangiogenesis therapeutic strategy may present certainly 
advantage of safety and low incident of drug resistant, and antiangiogenesis have 
potential to inhibit tumor invasion, and metastasis (Folkman, 2006). 
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1.3 Antiangiogenic drugs  
There are many antiangiogenic targeting molecules tested in the clinical trials 
and pre-clinical studies. However, one of well recognized angiogenesis factor is 
vascular endothelial growth factor (VEGF), which has been demonstrated to play a 
crucial role in regulating tumor angiogenesis (Petrova et al., 1999) and normal 
vascular development (Fong et al., 1995; Shalaby et al., 1995). VEGF is secreted by 
starving cancer cells and bind to the receptors in endothelial cell to elicit several 
endothelial cells response including microvascular permeability (Dvorak et al., 1995), 
secretion of matrix-degrading enzymes, endothelial cell proliferation, migration, and 
survival (Terman and Stoletov, 2001). Therefore, antiangiogenesis by inhibiting of 
VEGF/VEGFR signal pathway was considered a good strategy for anti-tumor 
treatment. United states Food and Drugs Administration (FDA), up-to-date, has 
approved several antiangiogenic drugs which are shown promising anti-tumor 
results in the cancer patients in the clinic (Folkman, 2007). Bevacizumab (Bec or 
Avastin) is a monoclonal antibody that neutralizes VEGF to prevent new vascular 
formation. Bevacizumab is a first approved antiangiogenic drug in 2004 for 
combinational treatment with chemotherapy for metastatic colorectal cancer (Cohen 
et al., 2007b; Ratner, 2004) . Continuingly, bevacizumab was approved for treatment 
of patients with non-small cell lung cancer (Cohen et al., 2007a), metastatic breast 
cancer (Spalding, 2008), galioblastoma (Cohen et al., 2009), and renal cell cancer 
(Summers et al., 2010). However, currently FDA recommends removing 
bevacizumab from the treatment for metastatic breast cancer patients because 
clinical outcome doesn’t show significant tumor inhibition and better patent survival 
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(Burstein, 2010). Sorafenib and sunitinib are small molecular inhibitors that can 
block not only VEGFR tyrosine kinase activity but also PDGFR activity as well 
(Gotink and Verheul, 2010).  In July 2011, FDA announces that bevacizumab is 
alternative option for some patients who treat in combination with chemotherapy. 
Sorafenib was approved by FDA for treatment of patients with renal cancer in 2005 
(Eto and Naito, 2006) and hepatocellular carcinoma in 2007 (Flaherty, 2007); 
Sunitinib was first antiangiogenic drugs approved for two different cancer types at 
same time, renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stoma 
tumor (GIST) in 2007 (Rock et al., 2007). So far, three FDA approved antiangiogenic 
drugs (Bevacizumab, Sorafenib and Sunitinib) are all belong indirectly strategy to 
inhibit vascular growth.  
 
1.4 Antiangiogenic drugs clinical hindrances  
Ideal, anti-tumor drugs should have superior therapeutic window, i.e. high 
therapeutic efficacy and high safety. Chemotherapy can provide good anti-tumor 
activity (Morgan et al., 2004) but low safety because it lacks cancer cell specific 
targeting, resulting in frequently severe side effects (Orditura et al., 2004). On the 
other hand, antiangiogenic strategy is a quite different anti-tumor strategy from 
chemotherapy by blocking oxygen and nutrients supply to the tumors to suppress 
tumor growth. Because of this unique therapeutic strategy, it proposed a couple of 
advantages. First, it would be less possibility to induce drug resistance because it 
targets genetically stable endothelial cell instead of targeting genetically unstable 
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tumor cells. Second, it would have less off-targeting issues because tumor 
associated endothelial cells are uniquely proliferating which are different from 
quiescent normal endothelial cells (Augustin et al., 1994; Denekamp, 1984). In vitro 
preclinical data and in vivo animal models indeed provided the experimental results 
to support these predictions that antiangiogenic therapy is effective therapeutic 
strategy with low incident of drug resistance and without virtual toxicity (Boehm et 
al., 1997). Compared to side effects induced by traditional chemotherapy, the toxicity 
could be ignored in antiangiogenic treatment. However, accumulating clinical 
evidence has changed these principles and shown that antiangiogenic agents still 
induce drug resistance (Schmidt, 2009) and side effects (Hasani and Leighl, 2011).   
 
1.4.1 Drug resistance 
When cancer patients are treated with antiangiogenic agents, several 
mechanisms will respond to the inhibition of tumor vascular formation to avoid it. 
Those emerging mechanisms can generalize two models of antiangiogenic drug 
resistance, in specially targeting VEGF/VEGFR pathway: one, adaptive resistance; 
and the other, intrinsic (pre-existing) non-responsiveness resistance. 
For adaptive resistance, tumor cells initially respond to anti-VEGF/VEGFR 
therapy and then adapt to treatment by inducing other angiogenic mechanisms to 
lead tumor relapse and progression. The induction of tumor vascular formation can 
be regulated by redundantly several angiogiogenesis mechanisms which contain at 
least four different mechanisms: activation other pro-angiogenic factors from tumor 
 6
cells, tumor-associated fibroblast, or stem cells (Fischer et al., 2007); bone marrow-
derived progenitor cells recruitment; increasing vessels protection by pericyte 
coverage; and enhancement of tumor cell invasion for oxygen and nutrients 
requirement (Ebos et al., 2009; Paez-Ribes et al., 2009). 
For intrinsic resistance, tumor vascular formation may regulate by multiple 
redundant angiogenesis factors which does not respond to antiangiogenesis 
monotherapy (Kerbel, 2009). Combination therapy to reduce drug resistance and 
further enhance therapeutic efficacy has been proposed; however, adverse effects 
cause patients in shorter progression-free survival (Tol et al., 2009).  
 
1.4.2 Side effects 
Anti-VEGF/VEGFR antibodies can block or neutralize angiogenesis induced 
by VEGF/VEGFR stimulation, and their less tumor specific targeting activity 
frequently lead off-target effects. In addition to tumor growth and survival, VEGF 
signaling pathway play an important role in normal physiological process to maintain 
homeostasis (Verheul and Pinedo, 2007). Example of side effects induced by anti-
VEGF/VEGFR drug treatment includes hypertension, proteinuria, and impaired 
wound healing. In addition to management side effects, antiangiogenic treatment 
also induces potential life-threatening complications, gastrointestinal perforation 
responds in short-term treatment and cardiac function failure under long-term 
treatment (Force et al., 2007; Kramer and Lipp, 2007). 
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1.5 The concepts of antiangiogenic therapy potential prevent drug resistance 
Multiple clinical trials have demonstrated that antiangiogenic therapy has clinical 
benefits, and some of antiangiogenic agents were approved by FDA. However, the 
emergence of drug resistant tumors in clinic has largely been unexpected compared 
with antiangiogenesis original principles. The potential mechanisms of drug 
resistance have been predicted by researchers and clinicians. They suggest some of 
possible treatment methods to ameliorate or avoid drug resistance. 
 
1.5.1 Chemotherapy strategy contain antitangiogenic effect 
The dose of chemotherapeutic agents is determined based on well 
established concept of maximum tolerant dose (MTD) in order to provide the best 
antitumor efficacy. However, 'the more frequent is better' or 'less is more' is a 
controversial issue. Higher dose is expected more anti-tumor effects but less 
survival benefits due to adverse effects in patents (Nieto, 2003; Roche et al., 2003). 
On the other hand, low dose of chemotherapy, which is also known as metronomic 
therapy, has been found to be able to reduce adverse effects but show 
antiangiogenic effects. In such low dose of chemotherapy, the dose sufficient to 
inhibit endothelial cells proliferation to from new vascular in tumor microenvironment 
but lower than the dose required killing the tumor cells is used (Citron et al., 2003; 
Tuma, 2003).   
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1.5.2 Combination therapy of antiangiogenic and chemotherapy agents 
The anti-tumor efficacy of chemotherapeutic agents also depends on 
blood stream. Thus, one potential rationale for the combination of antiangiogenic 
agent and chemotherapy is that antiangiogenic therapy can normalize vascular flow, 
resulting in increased oxygenation and delivery of chemotherpetic agents (Brown 
and Giaccia, 1998).  The other potential reason is that VEGF can serve as an anti-
apoptotic molecule that protects endothelial cells as well as cancer cells from 
apoptosis induced by standard treatment. Therefore, it is reasonable to combine 
chemotherapy with antiangiogenesis to enhance therapeutic efficacy of both the 
cytostatic and cytotoxic effect (Sweeney et al., 2001). 
 
1.5.3 Combination therapy of multiple antiangiogenic agents 
In tumor progression process, VEGF is not the only angiogenic factor 
secreted by tumor cells. It has been already known that several angiogenic factors 
can redundantly regulate tumor angiogenesis. When patients are treated by anti-
VEGF antibody, the hypoxia will be induced in tumor microenvironment. Not only 
tumor cells but also tumor-associated fibroblasts and microphages are stimulated by 
hypoxia, and then secret other angiogenic factors than VEGF to rescue hypoxia 
condition (Ivy et al., 2009). Therefore, it is not sufficient to inhibit tumor angiogenesis 
by monotherapy. Beside of VEGF, there are up to six different angiogenic factors 
and several intracellular factors have been recognized to modulate angiogenesis in 
different stages of breast cancer cell development (Relf et al., 1997). Thus, 
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treatment with multiple antiangiogenic agents may reduce the emergence of drug 
resistance risk in clinic. 
 
1.5.4 Combination therapy of antiangiogenic agents and biological 
molecular targeting agents 
Tumors with epidermal growth factor receptor (EGFR) overexpression/ 
mutation or human epidermal growth factor receptor-2 (HER-2) overexpression can 
be specifically selected for the treatments with the targeting agents that inhibit these 
receptor tyrosine kinases such as monoclonal antibodies or small molecule tyrosine 
kinase inhibitors. Because VEGF expression can be regulated by the EGFR family 
tyrosine kinases in tumors, these targeting agents also reach antiangiogenesis 
effects (Bruns et al., 2000; Clarke et al., 2001; Maity et al., 2000). However, clinical 
evidence shows that some tumor cells eventually become resistant to anti-EGFR 
antibody treatment, resulting in tumor recurrence because of increased VEGF 
expression (Viloria-Petit et al., 2001). Therefore, the combination therapy of 
antiangiogenic agents and biological molecular targeting therapy may be the 
alternative strategy to overcome targeted therapy resistance in some types of 
tumors. 
 
1.5.5 Antiangiogenic agents itself as multiple targeting therapy 
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As mention previously, several angiogenic factors can contribute to tumor 
progression in different stages. Currently, next-generation antiangiogenic agents that 
target multiple molecules have been developed. For example, Sunitinib or sorafenib 
as multiple tyrosine kinase inhibitors which can inhibit PDGFR and VEGFR activity. 
These agents block multiple molecular targets, resulting in  increased antitumor 
activity and decreased drug resistant potential at the same time (Teicher, 2010). 
  
1.6 Broad-spectrum angiogenesis inhibitors  
Over 100 years of cancer research, many critical signaling pathways involved in 
tumor initiation/progression has been identified. Now, it has been believed that 
several important signaling pathways can interplay with each other to redundantly 
regulate tumor progression. Therefore, even though one important oncogenic 
molecule is blocked by anti-tumor therapy, the other similar function molecular will 
express to rescue tumor development. Therefore, development of broad-spectrum 
angiogenic inhibitors is a new challenge for antiangiogenic agents.   
 
1.6.1 Endostatin 
Endostatin is an endogenous angiogenesis inhibitor which is divided from 
C-terminal of collagen XVIII to become a 20 kDa fragment molecule. O’reilly and 
collogues discovered endostatin in 1997 (O'Reilly et al., 1997) and determined it can 
inhibit endothelial cell proliferation, migration by binding to α5β1, αvβ3, and αvβ5 
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integrin receptors (Sudhakar et al., 2003).  Endostatin contains the broadest 
antiangiogenic spectrum activity though downregulation several angiogenesis 
pathway (Abdollahi et al., 2004) but induces less toxicity in mice (Zhang et al., 
2010). Under phase I clinic trail, endostatin showed virtually no toxicity and no drug 
resistance respond from patients who were received endostatin treatment everyday 
over 3 years. However, no significant clinical outcome in multiple endostatin clinical 
trials was observed (Herbst et al., 2002; Yang et al., 2006) due to poor anti-tumor 
efficacy and short half-life (Fu et al., 2009; Kulke et al., 2006). In China, Wang and 
collogues succeed to overcome short half-life issue of endostatin. Endostatin was 
approved by the State Food and Drug Administration (SFDA) to use in non-small cell 
lung cancer in China (Wang et al., 2005).  Although endostatin is not the only one 
factor containing broad antiangiogenic spectrum activity, this endogenous 
antiangiogenic protein has been tested in clinical trials more than any other proteins 
in recently decade.  
 
 1.6.2 Endostatin fusion protein 
In order to overcome the weakness of endostatin, researchers have 
attempted to modify this protein to increase either protein stability and/or anti-tumor 
efficacy. It has been shown that Fc domain of IgG is linked to N-terminal of 
endostatin to prolong endostatin protein stability and anti-tumor efficacy in 
comparison with original endostatin (Lee et al., 2008). An additional metal-chelating 
sequence (MGGSHHHHH) was integrated at the N-terminus of endostatin to provide 
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additional zinc binding site, and the zinc-binding significantly reduced thermal 
induced protein degradation (Jiang et al., 2009). This modified endostatin, which is 
named as endostar, is approved for the treatment of non-small cell lung cancer 
patients in China. Moreover, endostatin has been fused with HER2 monoclonal 
antibody, angiostatin, or antagonist integrin receptor RGD peptide to increase anti-
tumor efficacy and antiangiogenic activity in multiple cancer types including colon 
cancer, ovarian, and pancreatic cancer. (Belur et al., 2011; Jing et al., 2011; Shin et 
al.; Tysome et al., 2009; Tysome et al., 2011).  
 
1.7 Enzyme-prodrug therapy 
Enzyme-prodrug therapy is one of anti-tumor therapeutic strategies which need 
to metabolize or transform an inactive prodrug to an effective drug. Example of 
Enzyme-prodrug therapy are focused on inhibition of cell proliferation that preferable 
kill proliferation cell by blocking cell DNA/RNA synthesis and replication level.  
Enzyme-prodrug therapies can provide large amounts of tumor cells killing activity in 
short treatment cycles (Frei et al., 1988). However, there are some limitations for 
prodrugs in clinical application, including less tumor cell specific targeting activity, 
normal tissue off-targeting toxicity, and insufficient drug concentration in tumor sites 
by systemic treatment (Denny and Wilson, 1998; Evrard et al., 1999; Springer and 
Niculescu-Duvaz, 2000). When the cytotoxic drugs suppress tumor cell growth, they 
also kill the normal cell as well, particularly in the proliferating tissues such as bone 
marrow. Therefore, development of tumor specific targeting strategies for prodrug 
therapy becomes a big challenge in cancer research. After decades of cancer 
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research, researchers have identified several ways to activate prodrugs specifically 
in tumor sites, such as gene-directed enzyme prodrug therapy (GDEPT) (Dachs et 
al., 2009), virus-directed enzyme prodrug therapy (Grove et al., 1999), and antibody-
directed enzyme prodrug therapy (Bagshawe, 2009).  
Cytosine deaminase is a yeast enzyme which can catalyze enzymatic 
conversion of 5-flucytosine (5-FC) prodrug into chemodrug 5-fluorouracil (5-FU) 
(Pandha et al., 1999). Under this metabolism process, the cytosine deaminase 
linked with uracil phosphoribosyl transferase (we will refer to this fusion gene as CD) 
has been found to be able to enhance the enzymatic conversion compared to 
cytosine deaminase alone (Chung-Faye et al., 2001). This fusion strategy has been 
well established to enhance therapeutic effects in cancer cells (Erbs et al., 2000; 
Ramnaraine et al., 2003). However, systemic treatment with prodrugs induces off-
target effects link to side effects, and general disadvantage of prodrug system is still 
tumor targeting difficulty as described above.  
 
1.8 Working model Hypotheses  
As we mentioned before, indirect antiangiogenic drugs are more likely to induce 
drug resistance than direct ones because their targets are genetically unstable 
cancer cells. Recently, it has also been found that glioblastoma cancer stem-like 
cells could differentiate to endothelial cells which continue to provide nutrient to 
cancer cells and maintain cancer cells growth and survival. Alternatively, the 
strategy for antiangiogenesis should specifically target tumor endothelial cells rather 
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than cancer cells, and then it would provide greater clinical benefits than targeting 
tumor cells (Bautch, 2010). Therefore, it is promising to choose direct antiangiogenic 
agents which specifically target genetically more stable endothelial cells (Kerbel and 
Folkman, 2002; Kerbel, 1991). However, the direct antiangiogenic agents are mostly 
endogenous molecules and have some disadvantages including low protein stability 
and low anti-tumor activity. By linking with therapeutic molecules, their weak anti-
tumor activity and protein stability could be improved. In our study, we engineered 
endostatin used with CD in order to complement individual weakness and further 
provide a good therapeutic window including higher anti-tumor activity as well as low 
side effects and emergence of drug resistance. The major concept of this study is 
that EndoCD fusion protein has dual-targeting function. Not only does it have the 
capabilities of limiting endothelial cell growth (cytostaticity, by endostatin) but also 
killing cancer cells (cytotoxicity, by conversion of 5FC to 5FU at the tumor site). 
Endostatin is able to specifically target the fusion protein to tumor endothelial cells. 
CD is brought to tumor sites by its fusion with Endostatin, and therefore, 5-FC is 
converted to cytotoxic 5-FU only at the tumor sites. Therefore, EndoCD/5-FC 
provides dual targeting actvites including tumor antiangiogenesis and chemotherapy.  
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CHAPTER 2: MATERIAL AND METHOD  
 
2.1 Reagents.  
5-fluorouracil was purchased from InvivoGen (San Diego, CA), 5-fluorocytosine 
from Sigma (St. Louis, MO), and bevacizumab from the Department of Pharmacy at 
MD Anderson Cancer Center. 
 
2.2 Cell Lines.  
MDA-MB-231 and murine 4T1 breast adenocarcinoma cell lines were 
maintained in Dulbecco’s modified Eagle’s (DMEM)/F12 medium supplemented with 
10% fetal bovine serum (FBS). HUVECs were cultured in endothelial cell medium-2 
(Cambrex, East Rutherford, NJ). This colon cancer cell line was generated by our 
laboratory after several cycles of preselection from an orthotopic colon model that 
produced 100% liver metastasis and was maintained by G418 selection. 
 
2.3 Recombinant Protein Purification.  
The coding sequence of the human endostatin (Endo) was amplified from 
pPICZaA/hE (EntreMed) by polymerase chain reaction and cloned into the pET28 
bacterial expression vector (Novagen) to generate pET28Endo. The yeast cytosine 
deaminase-uracil phosphoribosyl transferase (CD) was sub-cloned from pORF5-
Fcy::Fur into pET28 (pET28CD). To generate pET28EndoCD, the fragment 
containing CD coding sequence was ligated to the 3’ end of Endo to allow 
expression of the fusion protein as a single polypeptide. Recombinant proteins 
(Endo, CD, and EndoCD) were expressed from pET28Endo, pET28CD, and 
 16
pET28EndoCD and purified from a liter of IPTG-induced bacterial culture based on 
the procedures previously described (Huang et al., 2001). The pellet was 
resuspended in Buffer A (0.1 M Tris-HCl, pH8.0 and 5 mM EDTA, 0.1% sodium 
deoxycholate) and incubated at 4C with the addition of lysozyme to a final 
concentration of 50µg/ml. The cells were sonicated and centrifuged at 8,000 X g for 
10 min. The pellet was washed twice with Buffer A and resuspended in Buffer B 
(0.05 M Tris-HCl, pH 8.0, 1% sodium lauroyl sarcosine (SLS), and 1 mM DTT) 4C 
overnight. After centrifugation, cleared supernatant was dialyzed sequentially 
against the following solution at 4C: Buffer C (0.05 M Tris-HCl, pH 8.0, and 1 mM 
DTT), Buffer D (0.05 M Tris-HCl, pH 8.0), and Buffer E (0.05 M Tris-HCl, pH 8.0, 
0.01 mM oxidized glutathione, and 1 mM reduced glutathione). A final dialysis step 
against 0.05 M Tris-HCl, pH 8.0 was performed to remove glutathione. The 
recombinant proteins were determined to be endotoxin free, and protein 
concentration was quantitated by using Bio-Rad dye method as described in the 
commercial protocol. The proteins were stored in aliquots with 0.05 M Tris-HCl, pH 
8.0 buffer in the -80C. The molecular weight of Endo, CD, and EndoCD is 20 kDa, 
40 kDa, and 60 kDa, respectively. Therefore, an equimolar ratio (1:2:3) of the 
proteins was used for all experiments. 
 
2.4 Cell Viability Assay.  
5 X 104 cancer cells MDA-MB-231 were passed in a 96-well plate overnight. 
Endo, CD and Endo-CD recombinant proteins with 100 g/ml 5-FC were put into 
each well. After 48 hr, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
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bromide) solution at 50 l per well (2 mg/ml; Sigma) was added into the cell culture 
and incubated for 2 hours, followed by addition of 100 l of dimethyl sulfoxide 
(Sigma) to each well. Absorbance at 570 nm was measured immediately using a 
multi-well scanner (Labsystems, Helsinki, Finland). 
 
2.5 Endothelial Tube Assay. 
Matrigel (BD Biosciences, San Jose, CA) was added to each well of a 96-well 
plate and allowed to polymerize.  A suspension of 5  103 HUVEC cells was passed 
into a Matrigel-coated well. The cells were treated with Endo, CD or EndoCD, and 
the treatment concentration was determined based on their respective molecular 
ratios. The cells were incubated for 4-6 hr at 37°C and viewed under a microscope. 
Five fields were viewed, and tubes were counted and averaged. All assays were 
performed in triplicate. 
  
2.6 Migration Assay.  
The inhibitory effect of endostatin on VEGF-induced chemotaxis was tested by 
using an 8-m Boyden chamber (Costar, Acton, MA) assay. HUVECs (1 X 104) were 
seeded in the upper chamber wells with 2% fetal bovine serum in the EBM medium 
(Cambrex, East Rutherford, NJ) and mixed together with Endo, EndoCD, or CD, and 
the treatment concentration was determined based on their respective molecular 
ratio. EGM2 medium (Cambrex) containing several growth factors were placed in the 
lower chamber as a chemo-attractant. The chamber was incubated at 37°C for 24 
hr. After the non-migrated cells were discarded and the upper wells were washed 
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with PBS, the filters were scraped with a Q-tip, and the cells were fixed in 4% 
formaldehyde in PBS and stained with 4',6-diamidino-2-phenylindole (DAPI) 
fluorescent dye. Three fields were viewed under a fluorescence microscope, and the 
cells were counted and averaged. All assays were performed in triplicate. 
 
2.7 Animal Models.  
All animals were maintained in the animal facility and experiments were carried 
out under the institutional guidelines of The University of Texas MD Anderson 
Cancer Center. For the syngeneic model, BALB/c mice were inoculated (mammary 
fat pad) with 1 X 105 4T1 murine breast adenocarcinoma cells. After the tumor 
volume reached 3-5 mm in diameter, equamolar amount of proteins (Endo, CD and 
EndoCD) were injected via tail vein (Endo 2.5 mg/kg) every other day. One hour 
after protein treatment, all groups received 5-FC (500 mg/kg) by intraperitoneal 
injection.  
For the orthotopic xenograft model, nude mice were inoculated with 3 X 106 
MDA-MB-231 human breast cancer cells in the mammary fat pad or 3 X 106 620-L-1 
human colon cancer cells in the cecal wall. After tumors were established 7 days 
post injection, EndoCD (60 mg/kg, twice per week) or bevacizumab (Avastin, 10 
mg/kg, once every two weeks) (Kabbinavar et al., 2003) was intravenously injected, 
and 5-FU (15 mg/kg, once per week) (Kabbinavar et al., 2003) or 5-FC (500 mg/kg; 
given 1 hr after EndoCD treatment) was administered by intraperitoneal injection. 
For practical clinical reasons, the treatment protocols for bevacizumab and 5-FU 
were essentially derived from previously established clinical doses and schedules 
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(Kabbinavar et al., 2003). Mice which received 10 mg/kg bevacizumab (once every 
two weeks, the clinical dose and schedule used in treating breast and colon cancer) 
or 60 mg/kg EndoCD (twice per week; protein dosage was based on endostatin 
clinical dosage 20 mg/kg and schedule was based on protein stability) via tail vein 
injection. Tumor volume was monitored by measuring luciferase signals using IVIS 
(In Vivo Imaging System; Xenogen, Alameda, CA). In a reduced-treatment 
experiment, the number of treatments given was decreased from 10 to 5. All protein 
treatments were given intravenously while chemical drugs were administered by 
intraperitoneal injection. 
 
2.8 Immunofluorescence Staining.  
Frozen sections (4-m) were fixed in cold 100% acetone for 5 min and then air-
dried. After immersion in 1X PBS for 15 min, the slides were incubated with rat 
monoclonal anti-CD31 antibody (BD Biosciences, San Jose, CA) at room 
temperature for 1 hr, rinsed with 1X PBS and then incubated with goat anti-rat 
immunoglobulin G conjugated to Texas Red (1:200; Jackson ImmunoResearch 
Laboratory, West Grove, PA) in the dark at ambient temperature for 60 min. CD31-
positive blood vessels were counted in 10–30 fields at 200X magnification in a 
blinded fashion. 
 
2.9 In vivo Apoptotic (TUNEL) Assay.  
For in vivo apoptotic assay, tumors were fixed in 10% formalin and embedded in 
paraffin blocks. Tissue sections were incubated with proteinase K (20 mg/ml in 
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10mM Tris-HCl, pH 7.4–8.0, for 15 min at 37oC), permeabilized in 0.1% Triton-X-100 
in 0.1% sodium citrate, and then labeled with the TUNEL (deoxynucleotide 
transferase-mediated dUTP-biotin nick end labeling) reaction mixture (Promega, 
Madison, WI) according to the manufacturer’s protocol. Briefly, biotinylated 
nucleotide mix and TdT enzyme were added and incubated at 37oC for 1 hr. The 
slides were washed in PBS, blocked in hydrogen peroxide, incubated in streptavidin 
horseradish peroxidase, developed in 3, 30-diaminobenzidine, and then 
counterstained with hematoxylin. The apoptotic cells (brown staining) were counted 
under a microscope. In each sample, 5 fields were randomly counted for the 
apoptotic cells. 
 
2.10 In vivo BrdU Incorporation Assay.  
MDA-MB-231 breast cancer cells were first injected into the mammary fat pad of 
nude mice, and when tumors reached 10 mm in diameter, mice were then treated 
once only with purified Endo (20 mg/kg), CD (40 mg/kg), EndoCD (60 mg/kg) 
proteins plus 500 mg/kg 5-FC, a clinically sufficient dose of 5-FU (15 mg/kg; 1X 5-
FU), or 10 times the clinically sufficient dose (150 mg/kg; 10X 5-FU). The choice of 
20 mg/kg Endo was based on a previous preclinical study(O'Reilly et al., 1997) and 
is also within the dosage range tested in the Phase I clinical trial(Herbst et al., 2002) 
(15-600 mg/m2 in human is equivalent to 4.8-194.4 mg/kg in mouse (Freireich et al., 
1966)). BrdU was intraperitoneally injected at 1 mg/kg 18 hr before tumors were 
harvested. Tumor sections were stained by BrdU antibody as previously described 
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(Mizoguchi et al., 2009), and the percentage of BrdU-positive cells was calculated by 
Automated Cellular Imaging System (ACIS III, Dako).  
 
2.11 LC/MS/MS.  
The HILIC and mass spectrometry condition was modified based on the 
previous studies (Kosovec et al., 2008; Pisano et al., 2005). First, tumor-bearing 
mice were administered with 500 mg/kg 5-FC, 10X-5-FU, or 60 mg/kg EndoCD plus 
500 mg/kg 5-FC. Tumor samples were harvested after 5-FU or EndoCD/5-FC 
treatment for 2 hours. Depending upon the weight of the tissues to be processed, a 
100 mg/mL tissue suspension in methanol containing 100 ng/mL of 5-Bromouracil 
(5-BrU, Sigma) was prepared as an internal standard; calculate the tissue volume as 
1 µL per mg of tissue weight. Tissue weight >200 mg prepare 100 mg/mL 
suspension; tissue weight <200 mg prepare 50 mg/mL suspension. (For example: 
250 mg tumor tissue = 250 µL volume; to prepare a 100 mg/mL suspension in 
methanol add 2250 µL of methanol + 100 ng/mL 5-BrU, the final volume upon 
homogenization will be 2500 µL at 100 mg/mL concentration). Tumor was 
homogenized by Mistral Ultrasonic tissue homogenizer and samples centrifuged for 
5 min at maximum speed at 4˚C to pellet any solid material. The cleared supernatant 
was then transferred into a sample vial for analysis by LC/MS/MS. 
 
2.12 Small Animal MRI.  
Cardiac MRI was carried out as previously described (Wang et al., 2010a). 
Mice were anesthetized with isoflurane in a circulatory heating stage throughout the 
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procedure. The dose was adjusted to maintain a respiratory rate between 20 and 50 
breaths per minute. Magnetic resonance imaging of the heart was conducted with a 
Bruker 7.0T scanner located in Small Animal Imaging Facility at the University of 
Texas MD Anderson Cancer Center. Image streams of serial short axis sections 
covering the whole heart (1.0 mm in thickness) were obtained with IG-Flash-cine 
sequences. End-systolic volume (ESV) and end-diastolic volume (EDV) of each 
section were manually segmented, and left ventricular ejection fraction was 
calculated by the following formula: LVEF = (ΣEDV-ΣESV)/ΣEDV. 
 
2.13 Hydroxyproline assay.  
This assay was modified from a previously described protocol (Kliment et al., 
2009; Woessner, 1961). Hearts harvested from treated and untreated mice (13-18 
mg) were hydrolyzed in 6N HCl at 50°C overnight in a glass tube and neutralized 
with NaOH and vacuum dried at 40°C. The pellet was resuspended in 1 ml of 5 mM 
HCl. A 1:10 dilution of each samples in a total volume of 200 µl was mixed with 100 
µl of chloramine T solution (2 ml H2O, 0.14 g chloramine-T, 8ml hydroxyproline 
assay buffer (11.4 g sodium acetate anhydrous, 7.5 g trisodium citrate dihydrate, 
and 77 ml isopropanol; final volume was 200 ml with H2O, pH 6.0, and 1.25 ml of 
Erlich’s reagent containing 6 g p-dimethylaminobenzaldehyde, 18 ml 60% 
perchlorate, and 78 ml isopropanol). The samples were incubated at 55°C for 20 min 
and read at OD570 nm. Trans-4-hydroxy-L-proline was used as standard curve to 
determine hydroxyproline concentration.  The control group was set as basal level 1. 
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2.14 Masson’s trichrome staining.  
Masson’s trichrome staining solution was purchased from Sigma. Tissue 
section was deparaffinized, rehydrated and put in Bouin's Solution at room 
temperature overnight. The samples were washed in running tap water for 5 min to 
remove the yellow color from the section, stained in Weigert's Iron Hematoxylin 
Solution for 5 min, washed again in running tap water for 5 min, and then stained in 
Biebrich Scarlet-Acid Fuchsin for 5 min. The slides were then placed in 
phosphomolybdic/ phosphotungstic acid solution for 10 min, transferred to Aniline 
blue for 5 min, placed in 1% acetic acid solution for 3 min, and then rinsed in distilled 
water.  Finally, the section was washed with 1% acetic acid for 1 minute and rinsed 
in distilled water. 
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CHAPTER 3: ENDOCD FUSION PROTEIN PURIFICATION 
 
In our previously study, we used gene therapy based strategy to determine anti-
tumor activity and antiangiogenic function of EndoCD (Ou-Yang et al., 2006). 
Although the technology of gene therapy is conceptually encouraging, it requires 
improvements in delivery methods to be efficiently used in clinical settings and to 
enhance its therapeutic effectiveness. The major concerns of gene therapy include 
delivery difficulties, low transfection efficiency, and unpredictable dose response. 
However, the technology for using protein therapy (e.g., antibodies) has been well 
established over the past decade. It has advanced to the extent that targeting 
delivery and dose responsiveness are all well controlled. Thus, the FDA has 
approved multiple antibodies for cancer therapy, and protein therapy has now 
become one of the important strategies in cancer treatment. Therefore, we expect 
that EndoCD fusion protein therapy will overcome deficiency of gene therapy and 
provide a new strategy for targeting angiogenesis and targeting chemotherapy to 
increase anti-tumor activity and reduce side effects. 
 
3.1 Construction of EndoCD protein expression  
To obtain EndoCD fusion protein, we first constructed human endostatin (Endo) 
or yeast cytosine deaminase-uracil phophoribosyl transferase (CD) protein 
expression plasmid (Figure 1A). Each Open Reading Frame (ORF) was subcloned 
into pET28 protein expression vector. We also subcloned both Endo and CD into a 
single pET28 vector to link Endo DNA sequence with CD DNA sequence (Figure 
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1B). Then, we purified each protein as described in Materials and Methods. For 
further experiments, we need to adjust each protein concentration to become 
equimolar. The approximately 1:2:3 ratios was based on 20 kDa of Endo, 40 kDa of 
CD, and 60 kDa of EndoCD protein molecular weight and would perform in the all 
experiments (Fig. 2).  
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Figure 1. Construction of Endo, CD, and EndoCD protein expression vector. 
 
 
(A) Vector map of the Endo, CD, and EndoCD fusion protein. EndoCD was clone 
into the pET28 vector (Novagen) and expressed in Escherichia coli (BL21) with 
an N-terminal histidine tag. 
  
(B) Amino acid sequence of EndoCD fusion protein. Endostatin (red), CD (blue). 
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Figure. 1  
A. 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
MHSHRDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIVRRA
DRAAVPIVNLKDELLFPSWEALFSGSEGPLKPGARIFSFDGKDVLRHPTWPQKSVWHGSDPNGRR
LTESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFMTASKEFVTGGMASKW
DQKGMDIAYEEAALGYKEGGVPIGGCLINNKDGSVLGRGHNMRFQKGSATLHGEISTLENCGRLE
GKVYKDTTLYTTLSPCDMCTGAIIMYGIPRCVVGENVNFKSKGEKYLQTRGHEVVVVDDERCKKIM
KQFIDERPQDWFEDIGEMNPLFFLASPFLYLTYLIYYPNKGSFVSKPRNLQKMSSEPFKNVYLLPQT
NQLLGLYTIIRNKNTTRPDFIFYSDRIIRLLVEEGLNHLPVQKQIVETDTNENFEGVSFMGKICGVSIVR
AGESMEQGLRDCCRSVRIGKILIQRDEETALPKLFYEKLPEDISERYVFLLDPMLATGGSAIMATEVL
IKRGVKPERIYFLNLICSKEGIEKYHAAFPEVRIVTGALDRGLDENKYLVPGLGDFGDRYYCV#  
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Figure 2. Endo, CD, EndoCD protein purification 
 
(A) SDS-PAGE analysis of the purified Endo, CD, and EndoCD protein. 
      Molecular weights of Endo, CD, and EndoCD are 20, 40, and 60 kDa, 
respectively. 
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Figure 2.  
 
A. 
 30
CHAPTER 4: INVESTIGATION OF ENDOCD FUSION PROTEIN BIOLOGICAL 
FUNCTION 
 
4.1 To study EndoCD antiangiogenic function and cell killing activity in vitro  
To characterize the biological activities of EndoCD, we purified the His-tagged 
recombinant proteins by using bacteria protein expression system. We then tested 
the antiangiogenesis activity of purified Endo and EndoCD by tube formation and 
migration assays using human umbilical vein endothelial cells (HUVEC). As shown 
in Figure 3, inhibition of angiogenesis by EndoCD was similar to that of Endo as both 
significantly decreased tube formation (Figure 3, upper panels) and the number of 
migrated cells (Figure 3, lower panels) compared with control (mock) or CD 
treatment. Next, we examined CD activity by measuring the enzymatic conversion of 
the prodrug 5-FC to cytotoxic 5-FU activity by using a cell viability assay in different 
cancer cell lines including 4T1 mouse mammary carcinoma; panO2 mouse 
pancreatic adenocarcinoma; MDA-MB-231, MDA-MB-468, and MCF7 human breast 
cancer cells; BE3, BIC-1, and SKG-4 human esophageal cancer cells lines (Figure 
4A-C). As shown in Figure 4, EndoCD evidently suppressed cell viability nearly as 
effectively as CD alone, suggesting the fusion protein maintains the 5-FC prodrug 
converting enzyme activity. 
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Figure 3. Antiangiogenic activites of EndoCD protein in vitro.  
 
Human Umbilical Vein Endothelial Cell (HUVEC) was treated with 2.5 M Endo, CD, 
or EndoCD. Upper panels, inhibition of HUVEC tube formation by EndoCD was 
similar to that of Endo. Tube formation was counted in three randomly selected 
areas. Lower panels, HUVEC migration was blocked by EndoCD under VEGF-
attracted condition.  
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Figure 3.
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Figure 4. Cancer cell killing activities of EndoCD/5-FC protein in vitro. 
 
Cancer cells lines that were treated with 100 g/ml of 5-FC and various 
concentrations of Endo, CD, or EndoCD. The cell viability of 5-FC alone group was 
set as 100%. , Endo/5-FC; , CD/5-FC; , EndoCD/5-FC.  
(A) Mouse 4T1 mammary carcinoma and panO2 pancreatic adenocarcinoma;  
(B) Human MDA-MB-231, MDA-MB-468, and MCF7 breast cancer cell lines;  
(C) Human BE3, BIC-1, and SKG-4 esophageal cancer cell lines
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Figure 4A. 
4T1                                                                    panO2
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Figure 4B. 
 
MBA-MB-231                                                         MBA-MB-468 
  
MCF7 
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Figure 4C. 
 
BE3                                                                       BIC1 
 
 
SKGT-4 
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4.2 To investigate EndoCD/5-FC biological activities in vivo 
4.2.1 To investigate the anti-tumor efficacy of EndoCD/5-FC in vivo 
We tested EndoCD/5-FC antitumor activity in vivo in a syngeneic 
mammary tumor model in which 4T1 breast cancer cells were injected into the 
mammary fat pad of BALB/c mice. An equamolar of each protein (2.5 mg/kg of 
Endo, 5 mg/kg of CD or 7.5 mg/kg of EndoCD) was administered into the tail vein of 
mice every other day (marked by arrows) for a total of 10 treatments, with 500 mg/kg 
5-FC (Chung-Faye et al., 2001) injection given 1 hr after protein treatment. The 
EndoCD/5FC-treated mice showed more potent tumor suppression (Figure 5A) and 
prolonged the overall mean survival rate (Figure 5B) compared with Endo/5-FC- or 
CD/5-FC-treated ones. These results indicate that the EndoCD fusion protein inhibits 
tumor growth more effectively than the two proteins alone.  
 
4.2.2 To investigate the biological function of EndoCD/5-FC-induced anti- 
         tumor and antiangiogenic activities in vivo 
The tumor samples were harvested from the protein-treated mice to 
analyze angiogenesis suppression as well as cancer cell death caused by the 
protein therapy. Tumor tissues were subjected to immunofluorescence staining with 
CD31 (a marker for endothelial cells) antibody and terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) assay to characterize program cell 
death. The results showed that EndoCD/5-FC decrease tumor vascular density and 
cause endothelial and cancer cell apoptosis more significantly than Endo/5-FC and 
CD/5-FC alone. We further merged signals from blood vessels and apoptosis by 
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double staining in all protein-treated tumor samples. One important finding, which 
was specially observed in the EndoCD/5-FC treatment tumor samples, is the 
majority of apoptotic signals (green color) surrounded and existed in endothelial cells 
(red color) (TUNEL/CD31 panel and inset, Figure 6). These phenomena indicate that 
apoptosis was ongoing in tumor endothelial cells treated with EndoCD/5-FC. 
Furthermore, apoptosis signals around the endothelial cells suggest that tumor cell 
also underwent program cell death process in EndoCD/5-FC treated tumor samples 
but not in other protein treatment samples. These results suggest that the specific 
cytotoxic activity observed in EndoCD/5-FC treated mice may come from increased 
5-FU local concentration. 
On the other hand, we also investigate the effects of EndoCD/5-FC protein 
on cancer cell proliferation.  We established orthotopic human breast cancer animal 
model and treated them with the fusion protein with the 5-FC or 5-FU under clinical 
condition. Then, we further determined the effects of fusion proteins on cell 
proliferation by in vivo BrdU incorporation analysis. The results indicate that the cells 
in EndoCD/5-FC-treated tumor samples exhibited less cell proliferation activity than 
the cells from tumor samples treated with other protein/prodrug combinations (Figure 
7A). This cell proliferation suppression activity of EndoCD/5-FC is even 10 times 
more potent than 5-FU treatment (Figure 7B), which encouraged us to measure 5-
FU concentration at local tumor area. 
 
4.2.3 To quantify 5-FU concentration in tumor  
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In order to further verify whether induction of cancer cell apoptosis and 
inhibition of cancer cell proliferation are indeed caused by high concentration of 5-
FU, we further determined 5-FU local concentration by liquid chromatography-mass 
spectrometry (LC/MS/MS) in tumors. According to LC/MS/MS analysis, 5-FU 
concentration from EndoCD/5-FC-treated tumors was about 7 times higher than that 
detected from the 10X 5-FU-treated tumors (Figure 8). Together with those in vivo 
function assays, we conclude that EndoCD/5-FC possesses ability to decrease 
density of tumor blood vessels and accumulate 5-FU concentration in tumor to 
induce apoptosis in both tumor and tumor endothelial cells. 
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Figure 5. EndoCD/5-FC anti-tumor activity in breast cancer orthotopic animal 
model 
 
(A) BALB/c mice were injected with 4T1 cells into mammary fat pad. Equimolar of 
each protein was injected intravenously and all mice were given 5-FC by 
intraperitoneal injection 1 hr after protein treatment. Arrow marker represents protein 
treatment times. EndoCD/5-FC had the best therapeutic efficacy in suppressing 
tumor growth and prolonged the overall mean survival of mice (B).
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Figure 5. 
A. 4T1 
 
 
 
 
 
 
 
 
 
B 
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Figure 6. Biological activity by EndoCD/5-FC in tumor microenvironment.  
 
Immunofluorescence staining of tumor tissues from mice treated with the indicated 
proteins and 5-FC combination (from Figure 5). Blood vessel was stained with 
vascular marker CD31 antibody (red) and apoptosis signal was detected by TUNEL 
assay staining (green). EndoCD/5-FC induced tumor vascular density reduction and 
endothelial and tumor cell apoptosis. Represent imaging is shown in left and 
quantification of each signal is shown in right.  
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Figure 6.  
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Figure 7. Inhibition tumor cell proliferation by EndoCD/5-FC  
 
(A) Tumor samples were labeled with BrdU (brown) antibody.  
(B) Quantification of BrdU signals. EndoCD/5-FC has more potent to inhibit cancer 
cell proliferation than with 10X 5-FU.  
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Figure 7.  
A. 
 
 
 
 
 
 
 
 
 
 
B. 
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Figure 8. Increased 5-FU concentration by EndoCD/5-FC in tumor 
microenvironment.  
 
5-FU concentration was detected by LC/MS/MS in tumor. Mice injected 5-FC, 10X-5-
FU via intraperitoneal injection, or EndoCD/5-FC via intravenous injection. 
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Figure 8.  
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CHAPTER 5: INVESTIGATION OF ENDOCD PROTEIN STABILITY 
To analyze the protein stability, we mixed an equimolar amount of each protein 
(Endo, CD, and EndoCD) with mice serum and incubated at 37 degree for the 
number of days. The samples were then subjected to western blotting and 
hybridized by anti-his-tag antibody. Quantification result shows that the half-life of 
Endo protein is less than one day, which consistent with reports from previous 
clinical (Eder et al., 2002). However, the EndoCD fusion protein has much longer 
half-life, which is about three days in the presence of mice serum (Figure 9).  
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Figure 9. The protein stability of EndoCD fusion protein.  
 
The stability of the EndoCD fusion protein is longer than Endo. (a) 12.5 M of each 
Endo, CD, or EndoCD were incubated in mice serum, and at the indicated time 
points, protein samples were harvested and analyzed by immunoblotting. (b) Protein 
bands were quantified and normalized to the day 0. , Endo; , CD; , EndoCD. 
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Figure 9.
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CHAPTER 6: INVESTIGATION OF ENDOCD/5FC TOXICITY 
To studies the acute toxicity of EndoCD fusion protein, mice were given 60 
mg/kg EndoCD by intravenous injection and then 500 mg/kg 5-FC intraperitoneally 
injected 1 hr after protein treatment. Mice blood were collected from orbital sinus 
every other day for one week, and liver functional markers aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT), as well as kidney 
function markers blood urea nitrogen (BUN) and creatinine in mice blood were 
detected. The analysis results indicate that all organ functional markers of liver and 
kidney (AST, ALT, BUN and creatinine) in EndoCD/5-FC-treated mice were in the 
normal range (Khatri et al., 2006) (Figure 10). Moreover, there were no sick signs 
found in EndoCD/5-FC treatment group. For example, no mice died more than two 
months, nor exhibited less appetite, less activity, and hair loss (data no shown). 
Together, the results indicate that EndoCD/5-FC would not have any acute toxicity 
nor induce anylife-threaten side effects in mice.  
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Figure 10. Acute Toxicity Assay of Endo, CD, and EndoCD fusion protein.  
 
EndoCD/5-FC has virtually no toxicity in mice. 20 mg/kg of Endo, 40 mg/kg of CD, or 
60 mg/kg of EndoCD was given to mice by intravenous injection, and all mice were 
injected with 500 mg/kg of 5-FC intraperitoneally 1 hr after the protein injection. Mice 
blood were then collected from orbital sinus every other day for one week, and liver 
and kidney function markers in the blood were determined. AST (A) and ALT (B) 
represent liver function; creatinine (C) and BUN (D) represent kidney function. The 
red line indicates the normal value. AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; BUN, blood urea nitrogen.  
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Figure 10.
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CHAPTER 7: ANTI-TUMOR ACTIVITY COMPARISON BETWEEN ENDOCD/5-FC 
AND BEC/5-FU 
To demonstrate EndoCD/5-FC would be a novel anti-tumor drug in clinic, we 
should compare therapeutic efficacy of EndoCD/5-FC and current clinical drugs. 
Based on biological function, Endo provide antiangiogenesis activity while cancer 
cell killing effects mostly come from 5-FU that is converted from 5-FC by CD. The 
mechanism of anti-tumor function of EndoCD/5-FC is similar with bec/5-FU which is 
used in several cancer types including metastatic colorectal cancer, non-small cell 
lung cancer (NSCLC), and breast cancer.  
To compare the therapeutic efficacy of EndoCD/5-FC and bec/5-FU, we 
performed two orthotopic tumor models including human breast cancer (MDA-MB-
231) and human liver metastasis colorectal cancer (620-L-1). SW620 is highly liver 
metastasis colon cancer cell line which was generated by several times re-
transplantation liver metastatic cancer cell in colon. 620-L-1 was developed by our 
laboratory and stably expresses luciferase protein for in vivo life image detection. 
Breast cancer cells and colon cancer cells were injected into mammary fat pad and 
cecal wall of colon, respectively. One week after tumor cell injection, EndoCD/5-FC 
or bec/5-FU was injected into the mice at equivalent clinical dose and treatment 
schedules. The results shows that EndoCD/5-FC provided significantly better anti-
tumor activity than bevacizumab or 5-FU alone (Figure 11A and 12A) and also 
prolonged overall mean survival rate than bev/5-FU (p=0.004) in the colon cancer 
model (Figure 12B). However, EndoCD/5-FC showed a similar therapeutic efficacy 
to bev/5-FU under this treatment schedules (Figure 11A and 12A).  
 55
To compare the therapeutic efficacy of EndoCD/5FC and bev/5-FU, we 
reduced total drug treatments which from 10 times treatment reduce to 5 times 
treatment and results shows that EndoCD/5-FC had better tumor suppression 
activity than bev/5-FU in the MDA-MB-231 breast cancer mouse model (Figure 11B) 
and the metastatic colon cancer mouse model (Figure 12C) when the tumor sizes 
were majored on tumor inoculation Day 42 and Day 35, respectively. 
As we mentioned in Chapter 1, anti-VEGF/VEGFR drug treatment could 
suppress tumor angiogenesis and tumor growth; however, it has recently been 
suggested that tumor cells escaped from cell death induced by these therapies may 
become refractory tumors  with high invasive and metastatic properties (Loges et al., 
2009). To further determine whether EndoCD/5-FC therapy also has this clinical 
weakness, we used 620-L-1 liver metastasis colorectal cancer cells as an analysis 
model. To monitor cancer cell growth and indicate metastatic tumors, 620-L-1 
cancer cells were trasnfected to stably express luciferase protein, which can be 
tracked by IVIS-100 live image system. On 35 days after tumor inoculation, mice 
treated with EndoCD/5-FC did not show significant liver metastasis, while the 
significant liver metastasis was observed in the mice treated with bev/5-FU (Figure 
13). Taken together (Figure 11, 12, and 13), these results suggest that EndoCD/5-
FC has potent therapeutic activity to control tumor growth and survival as well as 
metastasis.  
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Figure 11. Anti-tumor activity comparison of EndoCD/5-FC and bev/5-FU in an 
orthotopic human breast cancer mouse model.  
 
(A) Mice bearing 231 breast tumors were treated with the indicated drug 
combination, and growth of tumor volumes were monitored. EndoCD/5-FC showed 
significantly better anti-tumor activity than bevacizumab or 5-FU alone. However, 
EndoCD/5-FC showed a similar therapeutic efficacy to bev/5-FU under this 
treatment schedules. Arrows represent each protein treatment. 
(B) Reduced total drug treatments and EndoCD/5-FC had tumor suppression activity 
better than bev/5-FU in MDA-MB-231 breast cancer mouse model on tumor 
inoculation Day 42. (For detail schedule of reduced treatments, please refer to 
material and method.)  
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Figure 11. 
A. MDA-MB-231 
 
 
 
 
 
 
 
 
B. MDA-MB-231     
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Figure 12. Anti-tumor activity comparison between EndoCD/5-FC and bev/5-FU 
in an orthotopic human liver metastasis colorectal cancer mouse model.  
 
(A)EndoCD/5-FC shows significantly better anti-tumor activity than bevacizumab or 
5-FU alone and also prolong mice overall mean survival rate than bev/5-FU 
(p=0.004) in colon cancer model (B). However, EndoCD/5-FC did not show a 
significantly better therapeutic efficacy than bev/5-FU under this treatment 
schedules.  
(C) Reduced total drug treatments and EndoCD/5-FC had tumor suppression activity 
better than bev/5-FU on tumor inoculation Day 35. Arrows represent each protein 
treatment. (For detail schedule of reduced treatments, please refer to material and 
method.)  
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Figure 12. 
A. 620-L-1                                                           B. 620-L-1 
 
C.620-L-1
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Figure 13. Liver metastasis comparison between EndoCD/5-FC and bev/5-FU 
in an orthotopic human liver metastasis colorectal cancer mouse model.  
 
Mice bearing 620-L-1 colon cancer expressing luciferase were treated by EndoCD/5-
FC or bev/5-FU. Tumor metastasis signal was tracked by IVIS-100 image on Day 35 
after inoculation. The result shows EndoCD/5-FC treatment did not increase liver 
metastasis compared with bev/5-FU treatment group.
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Figure 13. 
620-L-1 
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CHAPTER 8: COMPARISON OF CARDIOTOXICITY BETWEEN ENDOCD/5-FC 
AND BEC/5-FU 
It has been known that bevacizumab can cause 1.7 to 3% left ventricular 
dysfunction incidence, and 5-FU is also well studied to induce ischemic 
complications in cancer patients (Yeh and Bickford, 2009). To determine the 
cardiotoxicity effects of those drugs including EndoCD/5-FC and bev/5-FU, we 
harvested serums from drugs-treated mice (from figures 11 and 12) to further detect 
troponin I, which is a biological marker for damage of cardiomyocyte. Troponin I 
serum level was dramatically increased in bev- and bev/5-FU-treated breast cancer 
mice model. On the other hand, mice treated with bev/5-FU are the only group 
showed high level of troponin I in colon cancer model (Figure 14). These results 
suggest bev/5-FU treatment may cause cadiomyocyte damage but EndoCD/5-FC 
may not. 
To further examine whether EndoCD/5-FC protein treatment affects cardiac 
function, we used small animal MRI to analyze end-diastolic volume (EDV) and end-
systolic volume (ESV) that allowed us to calculate the left ventricular ejection fraction 
(LVEF; LVEF = (ΣEDV-ΣESV)/ ΣEDV) (Wang et al., 2010a) of mice before 
(pretreatment basal level) and after treatment with bev/5FU or EndoCD/5FC. 
Representative EDV and ESV images are shown in upper panel of figure 15 and 
LEVF amounts are shown in lower panel of figure 15. LEVF was significantly 
decreased in bev/5FU-treated mice in post three-month treatment. On the other 
hand, LEVF was only slightly changed in EndoCD/5FC-treated mice even after six-
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month treatment. Therefore, EndoCD/5-FC protein therapy may provide great 
advantage because of minimal cardiac impact. 
To study the effect of EndoCD/5-FC and bev/5-FU on heart tissue, we 
analyzed the incidence of cardiac fibrosis which has abnormal collagen 
accumulation. Collagen amounts in heart tissues can be determined by indirectly 
detecting hydroxyproline or direct collagen trichrome staining. The heart tissues 
were collected from mice used in figure 15, and we found that higher hydroxyproline 
amount (Figure 16A) and collagen accumulation (blue color, Figure 16B) in heart 
from bec/5-FU-treated mice than hearts from the control mice and EndoCD/5-FC-
treated mice. 
One of critical VEGF biological function is maintain myocardial angiogenesis; 
and it has been demonstrated that ischemic cardiomyopathy would be induced by 
loss of VEGF in mice (Carmeliet et al., 1999). To exam the effects of EndoCD/5-FC 
and bev/5-FU on mice myocardial angiogenesis, we measured serum VEGF levels 
and also determined coronal vessels density by staining with vascular marker CD 31 
antibody. Then, we found that circulating VEGF levels significantly reduced in mice 
treated bev/5-FU but not in one treated with EndoCD/5FC (Figure 17). Moreover, CD 
31 signals, which indicate coronal vessel density, were also decreased in heart 
tissues of mice treated bev/5-FU but not in one treated with EndoCD/5FC (Figure 
18). Together, these results indicate that bev/5-FU treatment would potentially 
induce cardiomyopathy and/or cardiac function failure compared to EndoCD/5-FC 
treatment in cancer patients.   
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Figure 14. Cardiotoxicity Assay by detecting troponin I level. 
 
Drug-treated mouse serum were collected from two orthotopic mice tumor model 
including human breast cancer model (MDA-MB-231) and human liver metastasis 
colorectal cancer model (620-L-1) to detect circulating troponin I level by ELISA. 
EndoCD/5-FC treatment group did not induce cardiotoxicity in both mice tumor 
therapy model. Bec, bevacizumab 
 
(A) High troponin I level induced by bec or bec/5-FU treatment group in breast 
cancer model, indicating that Bec and bec/5-FU treatment could cause mice 
cardiacmyocyte damage. 
(B) Cardiactoxicity was observed only in bec/5-FU treatment mice in human liver 
metastasis colorectal cancer model.
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Figure 14. 
A. MDA-MB-231 
 
 
 
 
 
 
 
 
B. 620-L-1 
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Figure 15. Cardiac function detection by magnetic resonance imaging (MRI) in 
drugs-treated mice 
 
Upper panel is representative image of EDV (end of diastolic volume) and ESV (end 
of stoic volume). 
Left ventricular ejection fraction (LVEF) was calculated by (ΣEDV-ΣESV)/ ΣEDV 
from each treatment mice and shown in lower panel. Before drugs treatment, LVEF 
value was set as mice normal value. LVEF value was significantly reduced in bev/5-
FU treatment group and there was no significant change of LVEF value in 
EndoCD/5-FC treatment group after three- and six- month treatment. NS, no 
significance. (For detail schedule of reduced treatments, please refer to material and 
method.)  
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Figure 15. 
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Figure 16. Cadiac fibrosis detection in EndoCD/5-FC and bec/5-FU treatment 
mice heart. 
 
(A)Hydroxyproline assay. 
The hearts were harvested from mice treated with EndoCD/5-FC or bec/5-FU. We 
also collected the same age of mice heart as a normal control. The detection amount 
was normalized with the weight of heart tissue. The high proline hydroxylation was 
detected in the bev/5-FU treatment group, which is significantly higher than control 
mice. In contrast, there was no significant difference in proline hydroxylation 
between EndoCD/5-FC group and control mice. NS, no significance. 
 
(B) Trichrome staining.  
Direct method shows fibrosis phenomena in mice heart. The presence of fibrosis is 
shown in blue by trichrome staining of heart histological section. Similar results as 
(A) are shown.
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Figure 16. 
A.Hydroxyproline assay. 
 
 
 
 
 
 
 
 
B. Trichrome staining 
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Figure 17. Circulating VEGF level comparison in EndoCD/5-FC and bec/5-FU 
treatment mice 
 
Circulating VEGF level was lower in bev/5-FU-treated mice than control mice and 
there were no significantly changes in EndoCD/5-FC-treated mice compared with 
control mice. NS, no significance 
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Figure 17. 
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Figure 18. Coronal vessels density comparison in EndoCD/5-FC and bec/5-FU 
treatment mice 
 
Upper panels are representative images of coronal vascular density hybridizing by 
CD31 antibody (red) in mice heart tissue.  
Lower panel shows that coronal vascular density was significantly decreased in 
bev/5-FU treatment mice compared to control mice but not in EndoCD/5-FC-treated 
group. NS, no significance 
 
 73
Figure 18. 
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CHAPTER 9: SUMMARY OF CHAPTER 3 TO 8 AND DISCUSSION 
Antiangiogenesis, the novel anti-tumor concept by Judah Folkman, has 
become reality during over last three decades and been applied in clinic. Inhibition 
tumor growth by anti-VEGF/VEGFR monoclonal antibodies became a first approved 
antiangiogenic modality in clinic. Although anti-tumor efficacy was fully tested in 
preclinical studies, accumulating clinical reports have shown that these drugs have 
cytostatic function without curative potent and further induced tumor recurrence, 
tumor invasion and metastasis (Loges et al., 2009). Although targeting therapy 
provides predictable safety profile, systemic treatment interrupts normal organ 
homeostasis to induce side effects (Verheul and Pinedo, 2007). Therefore, 
development of the strategies to enhance therapeutic efficacy and targeting 
specificity under center principle of Judah Folkman will become a new challenge in 
next decade.  
In this study, we set up this challenge as a goal. Namely, we have attempted 
to develop a novel antiangiogenic drug which provides high therapeutic efficacy and 
decreases incident of tumor recurrence and the risk of tumor invasion and 
metastasis. Moreover, to provide the high efficacy, we also tried to increase 
targeting specificity to prevent off-target side effect and increase safety. Then, we 
finally developed a novel fusion protein EndoCD. Endostatin is broad-spectrum 
antiangiogenesis protein which can specifically target tumor vascular system 
(Avraamides et al., 2008). In addition, the fusion protein can increase 5-FU 
concentration, which is converted from 5-FC by CD, in the tumor microenvironment. 
Thus, EndoCD/5-FC offers not only antiangiogenesis by tumor vascular targeting but 
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also tumor targeting chemotherapy. Dual targeting effect shown here will provide 
curative benefits to cancer patients.   
Clinical antiangiogenic drugs belong to indirect antiangiogenesis agents that 
selectively target VEGF pathway. Although, VEGF pathway is important for tumor 
angiogenesis, it is also known essential for normal physiological maintenance 
(Verheul and Pinedo, 2007). Indirect antiangiogenesis agents also block VEGF 
function in normal organ, and it perhaps causes side effects. In the principle of 
EndoCD fusion protein, it is directly targeted to uniquely proliferating endothelial cell 
in tumor sites, and thus it would have decreased off-target potential (Kerbel, 1991). 
Moreover, by carrying chemotherapeutic drugs to tumor area, EndoCD enhances 
cytostatic effect at the same time. In order to prove the concept, we purified EndoCD 
fusion protein from bacteria expression system and determine antoangiogenic and 
cell killing activities in vitro and in vivo. EndoCD/5-FC induced endothelial cells and 
tumor cells apoptosis and inhibited tumor cell proliferation, and these anti-tumor 
activities further reduced tumor cell invasion and metastasis. We also demonstrated 
that EndoCD/5-FC fusion protein has dual targeting tumor antiangiogenic and tumor 
local chemotherapeutic activities. Together, EndoCD is expected to be able to 
decrease potential tumor recurrence and tumor metastasis.  
In the present study, we also compared EndoCD/5-FC anti-tumor activity and 
safety with a clinical antiangiogenic drug, bevacizumab and 5-FU combination. 
EndoCD/5-FC showed better anti-tumor and metastasis inhibition activities than 
bec/5-FU. In the safety profile, EndoCD/5-FC provide virtually no toxicity, especially 
cardiotoxicity and cadiac function failure, while bec/5-FU exhibited these toxicities. 
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Therefore, our studies demonstrated that EndoCD/5-FC may resolve the weakness 
of antiangiogenic and chemotherapeutic drugs and reveal a novel potential of 
antiangiogenic modality in clinic.  
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CHAPTER 10 FUTURE DIRECTIONS  
10.1 Improvement of currently protein expression system 
In our current protein purification system, when EndoCD fusion protein was 
expressed in E. coli, the majority of protein become aggregated and found in 
inclusion body of bacteria. Therefore, we first purified the inclusion body to get high 
purity of EndoCD protein, and then EndoCD was denatured and refolded though 
dialysis procedures. During dialysis procedure, EndoCD structure may be refolded 
from linear structure to different stages of tertiary structure. The quality of protein in 
each purification batches may vary due to dialysis procedure.. Therefore, we need to 
improve or modify currently protein expression system for future clinical application. 
 
10.1.1 To improve protein solubility in different protein expression. 
To improve protein solubility, we will test different approaches in our 
currently expression system including different expression vectors, different 
induction temperature, and modification of the linker. In figure 19A modification 
strategy map, we can either change linker or use different tag to test in different 
induction temperature. In this expression vector, high solubility of EndoCD protein 
can be induced in room temperature (23 ºC) or 4 ºC degree (Figure 19B). We will 
further purify soluble protein in large scale E. coli expression system.
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Figure 19. Solubility improvement of EndoCD protein in E. coli system 
 
(A) The strategy map of protein expression map. 
 
(B) EndoFlexCD protein (red color arrow) induction in different temperature. RT, 
room temperature; sup, soluble protein; pet, insoluble protein
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Figure 19. 
A. 
 
 
 
 
B. 
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10.2 To test the cancer stem cells (CSCs, TICs: tumor-initiating cells) killing 
activity of EndoCD/5-FC. 
Clinical data now suggest that antiangiogenic therapy leads to the 
progression of tumors by increasing invasion and metastasis, likely due to activation 
of the cancer stem cell population (Ebos et al., 2009; Paez-Ribes et al., 2009). 
Cancer stem cells (CSC, or tumor-initiating cells, TICs) have been considered to 
contribute to cancer initiation, progression and chemotherapeutic resistance (Al-Hajj 
and Clarke, 2004; Reya et al., 2001; Rossi et al., 2008). It has also been shown that 
glioma initiating cells have a greater ability to promote vascular endothelial growth 
which may confer enhanced angiogenesis for tumor cell survival and proliferation 
(Ricci-Vitiani et al., 2010; Wang et al., 2010b). Currently, there are no effective ways 
to target CSCs.  CSCs in different types of cancer have been gradually identified. 
For example, breast cancer stem cells (BCSCs, alternatively called breast tumor 
initiation cells, BTICs) can be isolated by sorting for CD44+CD24-/low cells (Al-Hajj 
et al., 2003) or Hoechst negative side population (SP) cells (Patrawala et al., 2005), 
and can also be enriched by spheroid culture and serial transplantations in 
immunodeficient mice (Ponti et al., 2005). These CSCs not only harbor the capability 
of self-renewal, but also are able to differentiate into multiple lineages of tumor cells 
growing in various types of distal organs. They have been shown to be resistant to 
the standard chemotherapy. Thus, we hypothesized that EndoCD/5-FC may 
selectively reduce breast cancer stem cells populations. 
 
10.2.1 To determine EndoCD/5-FC CSCs killing activities 
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After EndoCD/5-FC protein treatment, we found that EndoCD/5-FC 
selectively reduced the MDA-MB-231 and MCF-7 CD44+/CD24- population in a dose 
dependent manner (Figure 20A) as well as mammosphere formation (Figure 20B). 
These results suggest that EndoCD/5-FC may inhibit BCSC growth. We will expand 
the experiments to multiple breast cancer cell lines even primary tumor samples with 
different criteria of CSC phenomena in vitro and in vivo. The molecular mechanism 
for EndoCD/5FC-mediated BCSCs suppression should be interesting to further 
pursue.  For instance, if Endo is critical for targeting BCSCs, integrin αvβ1 in BCSCs 
may be important for maintenance of BCSC.  Once it becomes clear, we will logically 
pursue the appropriate direction. Alternatively, we can always use a nonbiased 
approach such as antibody arrays to identify which signal pathways might be 
activated/inactivated by EndoCD/5-FC treatment.  
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Figure 20. EndoCD/5-FC can selectively reduce breast cancer stem cell 
population. 
 
(A) To detect the CSC (TICs) population, surface markers CD44+/CD24- serve as 
an index. After EndoCD/5-FC treatment in two human breast cancer cell lines (MDA-
MB-231 and MCF-7) for 48 hours, 1X106 cells were processed for staining with 
FITC-conjugated CD44 and PE-conjugated CD24 antibodies, respectively, and then 
analyzed or sorted with BD flow cytometer. EndoCD/5-FC decreased breast stem 
cell population by dose dependent manner.  
 
(B) CSC (TICs) population was also validated by culturing mammospheres using 
MammoCultTM medium containing 4 ug/ml Heparin and 0.48 μg/ml hydrocortisone. 
EndoCD/5-FC has ability to inhibit breast cancer mammopheres formation. 
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Figure 20. 
A.MDA-MB-231                                                     MCF-7 
 
 
B. 
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